Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Clinical trial NCT05480384 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05480384
Sponsor: Brown University
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Esophageal Adenocarcinoma Esophageal Cancer HER-2 Protein Overexpression Gastroesophageal-junction Cancer

Start date: 2023-07-14
Primary completion: 2025-05-05
Enrollment: 1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.